Cost-effectiveness Study of Antidiabetic Drugs in Type 2 Diabetes Mellitus Patients From Mumbai, India


Autoria(s): Limaye, Dnyanesh; Todi, K.; Shroff, J.; Ramaswamy, A.; Kulkarni, P.; Limaye, Vaidehi; Fortwengel, Gerhard
Data(s)

2016

Resumo

Diabetes is fast gaining the status of a potential epidemic in India, with >62 million individuals currently diagnosed with the disease.1 India currently faces an uncertain future in relation to the potential burden that diabetes may impose on the country. An estimated US$ 2.2 billion would be needed to sufficiently treat all cases of type 2 diabetes mellitus (T2DM) in India.2 Many interventions can reduce the burden of this disease. However, health care resources are limited; thus, interventions for diabetes treatment should be prioritized.

Formato

application/pdf

Identificador

http://serwiss.bib.hs-hannover.de/frontdoor/index/index/docId/915

urn:nbn:de:bsz:960-opus4-9151

http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bsz:960-opus4-9151

http://serwiss.bib.hs-hannover.de/files/915/Cost-effectiveness_Study_of_Antidiabetic_Drugs_Type_2_Diabetes_Mellitus_Patients_From_Mumbai.pdf

Idioma(s)

eng

Direitos

http://creativecommons.org/licenses/by-nc-nd/4.0/

info:eu-repo/semantics/openAccess

Palavras-Chave #ddc:610
Tipo

article

doc-type:article